ADAPT I Ltd. - 20 Jun 2025 Form 4 Insider Report for Caris Life Sciences, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: CAI on Nasdaq
Reported as of: 20 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2025, 18:31:40 UTC
Source filing: View source filing
Reporting owner signature: ADAPT I Ltd., /s/ J. Russel Denton, Attorney-in-Fact

Key filing fact

ADAPT I Ltd. filed Form 4 for Caris Life Sciences, Inc. on 23 Jun 2025.

Key facts

This page summarizes ADAPT I Ltd.'s Form 4 filing for Caris Life Sciences, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2025, 18:31.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0002072411 Primary reporting owner

ADAPT I Ltd.

Relationship: 10%+ Owner
Address: C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature: ADAPT I Ltd., /s/ J. Russel Denton, Attorney-in-Fact
Signature date: 23 Jun 2025

CIK 0002072412

Carisome I, L.P.

Relationship: 10%+ Owner
Address: C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature: Carisome I, L.P., /s/ J. Russel Denton, Attorney-in-Fact
Signature date: 23 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAI transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +3,500,003
Change %: +26%
Price: $0.000000
Shares after: 16,943,232
Date: 20 Jun 2025
Ownership: See Footnotes
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CAI transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -14,000,000
Change %: -100%
Price
Shares after: 0
Date: 20 Jun 2025
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 3,500,003
Exercise price: $0.000000
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

ADAPT I Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock.

Footnote F2

The Common Stock reported herein includes 8,528,805 shares of Common Stock held of record by ADAPT I Ltd. and 8,414,427 shares of Common Stock held of record by Carisome I, L.P. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert is the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Footnote F3

The preferred stock reported herein includes 3,500,003 shares of Common Stock underlying Series A Preferred Stock held of record by ADAPT I Ltd..

SEC remarks

David Halbert and Caris Halbert, L.P. are filing a separate Form 4 with respect to the transactions reported herein.